- Symbiosis has manufactured its first 10,000-vial batch at its new FDA-inspected and MHRA-licensed facility in Stirling, UK.
- The production supports a Phase III cancer immunotherapy programme and marks a milestone in the company’s sterile manufacturing capacity expansion.
Symbiosis has announced the manufacture of its first 10,000-vial batch at the company’s new sterile manufacturing facility in Stirling, UK. The batch was produced for a long-standing client and supports the development of a cancer immunotherapy currently in Phase III clinical trials.
The production run represents a milestone in Symbiosis’ planned expansion of sterile manufacturing capacity, aimed at meeting increasing global demand for injectable medicines. The FDA-inspected and MHRA-licensed facility is designed to support programmes from clinical development through to commercial supply, offering increased capacity and operational flexibility.
According to the company, the expanded site enables larger batch sizes, supports additional client programmes, and provides continuity for organisations preparing for late-stage development and commercial launch. The facility forms part of Symbiosis’ wider contract manufacturing services for sterile drug products.
“Manufacturing this first batch of 10,000 vials in our state-of-the-art facility is a pivotal moment for Symbiosis.”
Colin MacKay, Chief Executive Officer of Symbiosis
Symbiosis said the achievement follows sustained growth since its founding in 2011. The company now employs more than 150 specialists across four buildings in Stirling and continues to invest in people, quality systems, and advanced manufacturing capabilities as it expands its role as a CDMO supporting global pharmaceutical clients.
